Ізраїль - арабська - Ministry of Health

teva pharmaceutical indust.ltd - donepezil hydrochloride 5 mg - tablets - donepezil - treatment of mild to moderately severe alzheimer's dementia.

Ізраїль - арабська - Ministry of Health

abic ltd. - atenolol 25 mg - tablets - beta blocking agents, selective - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction.

Ізраїль - арабська - Ministry of Health

bayer israel ltd - norethisterone acetate 5 mg - tablets - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

Ізраїль - арабська - Ministry of Health

sanofi - aventis israel ltd - risedronic acid as sodium 150 mg - film coated tablets - risedronic acid - treatment of postmenopausal osteoporosis.prevention of postmenopausal osteoporosis.

Ізраїль - арабська - Ministry of Health

salomon,levin & elstein ltd - amoxicillin trihydrate 500 mg - capsules - amoxicillin - infections caused by amoxycillin - susceptible organisms. prevention of bacteremia in patients at risk of developing bacterial endocarditis.

Ізраїль - арабська - Ministry of Health

salomon,levin & elstein ltd - amoxicillin as trihydrate 875 mg; clavulanic acid as potassium salt 125 mg - film coated tablets - ampicillin, combinations - short-term treatment of bacterial infections at the following sites: upper/lower respiratory tract infections, genito-urinary tract infections, skin and soft tissue infections, bone and joint infections, dental infections and other infections.

Ізраїль - арабська - Ministry of Health

sanofi - aventis israel ltd - hydrochlorothiazide 12.5 mg; ramipril 2.5 mg - tablets - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

Ізраїль - арабська - Ministry of Health

abic ltd. - ofloxacin 200 mg - tablets - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as:- acute, chronic, or recurrent lower respiratory tract infections (bronchitis) pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci). - chronic and recurrent infections of the ear, nose, and throat. ofloxacin is in general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci. - infections of soft tissues and skin. - infections of the bones and joints. - abdominal infections including infections in the pelvis minor and bacterial enteritis. - infections of the kidney, urinary tract, and genital organs, gonorrhoea.prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).

Ізраїль - арабська - Ministry of Health

salomon,levin & elstein ltd - loteprednol etabonate 5 mg / 1 ml - ophthalmic suspension - loteprednol - lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to otain an advisable diminution in edema and inflammation. lotemax is less effective than prednisolone acetate 1 % in two 28 day controlled clinical studies in acute anterior uveitis, where 72 % of patients treated with lotemax experienced resolution of anterior chamber cells, compared to 87 % of patients treated with prednisolone acetate 1 % . the incidence of patients with clinically significant increases in iop (> or = 10 mmhg) was 1 % with lotemax adn 6 % with prednisolone acetate 1 %. lotemax should not be used in patients who require a more potent corticosteroid for this indication. lotemax is also indicated for the treatment of po

Ізраїль - арабська - Ministry of Health

sanofi - aventis israel ltd - ramipril 2.5 mg - tablets - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.